| dc.creator | Vavougios G.D., Mavridis T., Artemiadis A., Krogfelt K.A., Hadjigeorgiou G. | en |
| dc.date.accessioned | 2023-01-31T10:30:27Z | |
| dc.date.available | 2023-01-31T10:30:27Z | |
| dc.date.issued | 2022 | |
| dc.identifier | 10.1016/j.bbadis.2022.166430 | |
| dc.identifier.issn | 09254439 | |
| dc.identifier.uri | http://hdl.handle.net/11615/80532 | |
| dc.description.abstract | Type I interferon (IFN-I) signalling represents a major target for modulation in a virus' bid for latency. IFN-I perturbations are also present in such as Alzheimer's disease (AD) and multiple sclerosis (MS), where viral infections are known to increase symptomatic burden. IFN-I modulation such as via IFNβ-1a, an established MS treatment, has been researched to a limited extent to both AD and COVID-19. In this mini review, we present emerging research on trained immunity as a pathogenetic basis for Alzheimer's disease and the emerging context for IFNβ-1a repositioning, via mechanisms shared with multiple sclerosis and induced by viral infections. © 2022 Elsevier B.V. | en |
| dc.language.iso | en | en |
| dc.source | Biochimica et Biophysica Acta - Molecular Basis of Disease | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129968384&doi=10.1016%2fj.bbadis.2022.166430&partnerID=40&md5=01ef8009970fb3319681bbff03e6eba7 | |
| dc.subject | beta1a interferon | en |
| dc.subject | interferon inducible transmembrane protein 3 | en |
| dc.subject | membrane protein | en |
| dc.subject | oligoadenylate synthetase 1 | en |
| dc.subject | unclassified drug | en |
| dc.subject | beta interferon | en |
| dc.subject | Alzheimer disease | en |
| dc.subject | coronavirus disease 2019 | en |
| dc.subject | epigenetics | en |
| dc.subject | human | en |
| dc.subject | immunological memory | en |
| dc.subject | immunomodulation | en |
| dc.subject | innate immunity | en |
| dc.subject | multiple sclerosis | en |
| dc.subject | nervous system inflammation | en |
| dc.subject | Review | en |
| dc.subject | type I interferon signaling | en |
| dc.subject | virus immunity | en |
| dc.subject | virus infection | en |
| dc.subject | Alzheimer Disease | en |
| dc.subject | COVID-19 | en |
| dc.subject | Humans | en |
| dc.subject | Interferon-beta | en |
| dc.subject | Multiple Sclerosis | en |
| dc.subject | Virus Diseases | en |
| dc.subject | Elsevier B.V. | en |
| dc.title | Trained immunity in viral infections, Alzheimer's disease and multiple sclerosis: A convergence in type I interferon signalling and IFNβ-1a | en |
| dc.type | other | en |